RSS Feeds
Dimethyltriazenoimidazole Carboxamide Therapy of Malignant Glucagonoma
- GARY M. STRAUSS, M.D.;
- SIGMUND A. WEITZMAN, M.D.; and
- THOMAS T. AOKI, M.D.
Excerpt
Pancreatic alpha cell tumors that secrete glucagon have stimulated considerable interest recently. They have been associated with a striking and distinctive clinical syndrome characterized by the skin rash of necrolytic migratory erythema, weight loss, glucose intolerance, anemia, stomatitis, and hepatic metastases in most cases
(1). Streptozocin has been used with sporadic, though not consistent, success. Efficacy for dimethyltriazenoimidazole carboxamide (DTIC) in this disease has been suggested in a single previous case report (2). We report here a rather remarkable response to DTIC in a patient with the malignant glucagonoma syndrome.
A 43-year-old white man presented to Massachusetts General Hospital in
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
The authors thank Drs. Gordon Weir and Sheldon Kaufman for referring this patient to our care and Dr. Kenneth McKusick for assisting in the interpretation of the liver scans.
Article and Author Information
-
This study was supported by the Edwin T. White Fund. Dr. Strauss is a recipient of a Regular Clinical Fellowship from the American Cancer Society, Inc., New York, New York. Dr. Weitzman is a recipient of a National Research Service Fellowship (CA-09321-01). Dr. Aoki is an Investigator, Howard Hughes Medical Institute.
